FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia

By Newsroom America Feeds at 1 Aug 2017

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569421.htm

Categories:
Tags:

[D] [Digg] [FB] [R] [SU] [Tweet] [G]

NEWSMAIL